A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-Acting β2-Agonist

Trial Profile

A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-Acting β2-Agonist

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Oct 2017

At a glance

  • Drugs Tralokinumab (Primary)
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Acronyms STRATOS2
  • Sponsors AstraZeneca
  • Most Recent Events

    • 12 Oct 2017 Status changed from active, no longer recruiting to completed.
    • 10 Aug 2017 Planned End Date changed from 28 Sep 2017 to 21 Sep 2017.
    • 23 Mar 2017 Planned primary completion date changed from 1 May 2017 to 30 Apr 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top